LUCENTIS RANIBIZUMAB

Get an overview of LUCENTIS (ranibizumab injection, solution), including its generic name, formulation (i.e. pill, oral solution, injection, inhaled medicine) and why it’s used. The medication in LUCENTIS can be sold under different names.

Refer to the “Also Known As” section to reference different products that include the same medication as LUCENTIS.

Drug Basics

Brand Name: LUCENTIS

Generic Name: RANIBIZUMAB

Drug Type: HUMAN PRESCRIPTION DRUG

Route: INTRAVITREAL

Dosage Form: INJECTION, SOLUTION

Data Current As Of: 2019-11-18

Indications and Usage, Diabetic Retinopathy (1.4) 04/2017
Dosage and Administration (2) 03/2018
Dosage Forms and Strengths (3) 03/2018

indications & usage

LUCENTIS is indicated for the treatment of patients with:

LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1.1)
  • Macular Edema Following Retinal Vein Occlusion (RVO) (1.2)
  • Diabetic Macular Edema (DME) (1.3)
  • Diabetic Retinopathy (DR) (1.4)
  • Myopic Choroidal Neovascularization (mCNV) (1.5)

neovascular (wet) age-related macular degeneration (amd)

 

macular edema following retinal vein occlusion (rvo)

 

diabetic macular edema (dme)

 

diabetic retinopathy (dr)

 

myopic choroidal neovascularization (mcnv)

 

drug interactions

Drug interaction studies have not been conducted with LUCENTIS.

LUCENTIS intravitreal injection has been used adjunctively with PDT. Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (± 2 days) after PDT.

patient counseling information

Advise patients that in the days following LUCENTIS administration, patients are at risk of developing endophthalmitis. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise the patient to seek immediate care from an ophthalmologist [see Warnings and Precautions (5.1) ].

LUCENTIS® (ranibizumab injection)
Manufactured by:
Genentech, Inc.
A Member of the Roche Group
1 DNA Way
South San Francisco, CA 94080-4990
LUCENTIS® is a registered trademark of Genentech, Inc.
©2018 Genentech, Inc.

Representative sample of labeling (see the HOW SUPPLIED section for complete listing):

This drug label information is as submitted to the Food and Drug Administration (FDA) and is intended for informational purposes only. If you think you may have a medical emergency, immediately call your doctor or dial 911. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Search Drugs and Medication

Or Browse by Name